PIA
HRTX icon

Piedmont Investment Advisors’s Heron Therapeutics HRTX Stock Holding History

Piedmont Investment Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,108
Closed -$43K – 1605
2018
Q2 		$43K Buy
+1,108
New +$35.3K ﹤0.01% 1343

Other funds holding HRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Piedmont Investment Advisors's HRTX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Heron Therapeutics (HRTX) in Q3 2018, closing a stake of 1,108 shares — an estimated $43K sold.

Piedmont Investment Advisors first reported a position in HRTX in Q2 2018 and held it in 1 quarter. The position peaked at $43K in Q2 2018. 194 funds tracked by Wall St. Rank hold HRTX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Heron Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 1,108 Heron Therapeutics shares in Q3 2018, an estimated $43K.
  • Piedmont Investment Advisors first reported a position in Heron Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Heron Therapeutics position peaked at $43K in Q2 2018.
  • 194 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.